18F-FDG高摄取甲状腺偶发瘤:情境化解读的重要性
该研究回顾分析2007年1月至2015年1月一家综合癌症中心45,680次PET/CT中的500例18F-FDG高摄取甲状腺偶发瘤患者,362例有确认死亡或超过12个月临床随访。中位总生存20个月,180例死亡中92.2%死于原发恶性肿瘤、7.2%死于非癌症原因、1例(0.6%)死于偶发甲状腺髓样癌;131例适合细胞学或组织病理学评估者中47例(36%)为偶发甲状腺癌。作者认为应先考虑基础恶性肿瘤预后,可考虑主动监测。
要点
- 18F-FDG高摄取甲状腺偶发瘤患者中位总生存仅20个月,死亡主要归因于原发恶性肿瘤(92.2%)。
- 131例适合细胞学或组织病理学评估者中47例(36%)为偶发甲状腺癌,仅1例(0.6%)死于甲状腺癌。
- 原发恶性肿瘤18F-FDG高摄取、原发恶性肿瘤晚期及临床医生决定不检查甲状腺偶发瘤均为死亡预测因素。
核心结论
- 18F-FDG高摄取甲状腺偶发瘤患者总生存差,源于基础恶性肿瘤的预后,在检查该偶发瘤之前、尤其在积极治疗之前必须考虑基础恶性肿瘤。
- 作者建议对该组患者可考虑主动监测。
研究设计与样本
- 回顾性 review,2007年1月至2015年1月在一家综合癌症中心行45,680次PET/CT,识别2,588份提及甲状腺的18F-FDG PET/CT报告。
- 排除非高摄取甲状腺结节、弥漫性18F-FDG摄取、已知甲状腺癌、甲状腺邻近异常及重复检查后,识别500例(1.1%)甲状腺偶发瘤患者,其中362例有确认死亡或超过12个月临床随访。
- 收集年龄、性别、原发恶性肿瘤、总生存、甲状腺癌特异性生存、细针穿刺细胞学(FNA)及组织病理学资料至2016年1月,行多因素logistic回归与生存分析。
主要发现
- 362例分析患者中65%为女性,中位年龄65岁(范围19-96岁),中位随访24个月(范围1-103个月)。
- 淋巴系统、肺及结直肠恶性肿瘤是最常见的分期指征;中位总生存20个月(四分位距9.5-39个月)。
- 180例观察到的死亡中92.2%死于所检查的原发恶性肿瘤,7.2%死于非癌症原因,1例(0.6%)死于偶发检出的甲状腺髓样癌。
- 原发恶性肿瘤18F-FDG高摄取、该恶性肿瘤晚期及临床医生决定不检查18F-FDG高摄取甲状腺偶发瘤均为死亡预测因素,风险比分别为8.5、3.0和3.3,95%CI分别为4.6-15.8、2.3-3.9和2.0-5.0(P<0.001)。
- 131例适合细胞学或组织病理学评估的患者中47例(36%)为偶发甲状腺癌(24例乳头状癌、11例恶性FNA、5例嗜酸细胞/Hürthle细胞、2例髓样癌、1例滤泡癌、4例基础恶性肿瘤转移)。
关键数值与推荐
- 2015年美国甲状腺协会指南强烈推荐对所有1 cm或以上的18F-FDG高摄取结节行超声和细针穿刺细胞学(FNA)检查。
- 18F-FDG高摄取甲状腺偶发瘤约占因恶性肿瘤分期或疗效评估而显像患者的2.5%,其中约35%为甲状腺癌。
临床怎么用
- 作者认为,在检查18F-FDG高摄取甲状腺偶发瘤之前、尤其在积极治疗之前必须考虑基础恶性肿瘤,作者建议对该组患者可考虑主动监测。
- 2015年美国甲状腺协会指南强烈推荐对所有1 cm或以上的18F-FDG高摄取结节行超声和细针穿刺细胞学(FNA)检查。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
18F-FDG-avid thyroid incidentaloma (TI) is seen in approximately 2.5% of patients imaged for staging or response assessment of malignancy and represents thyroid cancer in approximately 35% of cases. Consequently, the 2015 American Thyroid Association guidelines strongly recommend investigation of all 18F-FDG-avid nodules 1 cm or larger with ultrasound and fine-needle aspiration cytology (FNA). This study aimed to assess the overall and thyroid cancer-specific survival in a large cohort of patients with 18F-FDG-avid TI with long-term follow-up to assess the validity of this approach. Methods: Retrospective review of 45,680 PET/CT scans performed at a comprehensive cancer center from January 2007 to January 2015 identified 2,588 18F-FDG PET/CT reports referring to the thyroid. After exclusion of nonavid thyroid nodules, diffuse 18F-FDG uptake, known thyroid cancer, abnormalities adjacent to the thyroid, and repeat studies, 500 patients (1.1%) with TI were identified, of whom 362 had confirmed death or more than 12 mo of clinical follow-up. Variables including age, sex, primary malignancy, overall survival, thyroid cancer-specific survival, FNA, and histopathology were collected until January 2016. Multivariate logistic regression and survival analysis were performed. Results: The 362 analyzed patients (65% female) had a median age of 65 y (range, 19-96 y) and follow-up of 24 mo (range, 1-103 mo). Lymphoid, lung, and colorectal malignancy were the most common staging indications. Median overall survival was 20 mo (interquartile range, 9.5-39 mo). Most of the 180 observed deaths were due to the primary malignancy under investigation (92.2%) or to causes not related to cancer (7.2%); one patient (0.6%) died from incidentally detected medullary thyroid cancer. 18F-FDG avidity in the index malignancy, an advanced stage for that malignancy, and a clinician decision not to investigate 18F-FDG-avid TI were all predictors of mortality, with hazard ratios of 8.5, 3.0, and 3.3, respectively, and 95% confidence intervals of 4.6-15.8, 2.3-3.9, and 2.0-5.0, respectively (P < 0.001). Of 131 patients suitable for cytologic or histopathologic evaluation, 47 (36%) had incidental thyroid cancer (24 papillary, 11 malignant FNA, 5 oncocytic/Hürthle cell, 2 medullary, 1 follicular, and 4 metastases from underlying malignancy). Conclusion: Overall survival with 18F-FDG-avid TI was poor because of the prognosis associated with underlying malignancy, which must be considered before investigation of 18F-FDG-avid TI and certainly before aggressive treatment. Active surveillance should be considered in this group of patients.
引用
- Pattison DA, Bozin M, Gorelik A, et al. 18F-FDG-Avid Thyroid Incidentalomas: The Importance of Contextual Interpretation. J Nucl Med. 2017. PMID: 29025986. doi:10.2967/jnumed.117.198085
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。